Just four months after ending an 18-year stint as chief executive of BioMarin, Jean-Jacques Bienaimé has been named chairman of Owkin, a specialist in applying artificial intelligence to the discovery and development of drugs and diagnostics.
Owkin said Bienaimé will help to grow the company, including taking it through its next fundraising round and expanding its drug discovery, drug development and diagnostics capabilities.
